Trial Profile
Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 13 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 17 Jun 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.